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ABSTRACT
Venous thromboembolism (VTE) is the most preventable cause of in-hospital death. 
Hospital-related VTE is associated with over 50% of VTE episodes occurring either du-
ring or after hospitalization. Selective thromboprophylaxis is the recommended approa-
ch for inpatients. Patient selection for thromboprophylaxis requires VTE risk stratifica-
tion, including either the baseline disease plus additional risk factors or risk assessment 
standardized models (RAM). Risk categories guide the thromboprophylaxis selection 
to include general, mechanical, pharmacological, or combination measures. Although 
thromboprophylactic protocols have been available for decades, many patients at risk 
(20% to 75%) still do not receive the recommended thromboprophylaxis. This study 
purpose is to alert to the relevance of thromboprophylaxis and to guide the strategies to 
arrange hospital thromboprophylaxis programs in Brazilian settings.
Keywords: Venous thromboembolism; risk factors; hospitalization; primary prevention.
Open access under CC BY-NC-ND license.
MARCOS DE BASTOS ET AL.
88 Rev Assoc Med Bras 2011; 57(1):87-97
INTRODUCTION
Venous thromboembolism (VTE) comprises both deep 
venous thrombosis (DVT) and pulmonary embolism 
(PE)1-6. VTE is the main preventable cause of in-hospital 
death, and venous thromboprophylaxis is the initial strat-
egy to improve safety of hospitalized patients7,8. However, 
even after decades of disclosure of thromboprophylactic 
regimens, a significant proportion of patients at thrombo-
embolic risk does not receive thromboprophylaxis during 
hospitalization9-12. VTE diagnosis in hospitalized patients 
might require clinical search for a second disease in a pa-
tient already ill, new tests and dierential diagnoses, ex-
tended hospitalization, among other problems8,13,14. Over a 
half thromboembolic events occurring in the community 
are associated with hospitalization or previous institution-
alizations15. This study purpose is to discuss the need for 
implementing hospital thromboprophylaxis prevention 
programs and explain the principles of current thrombo-
prophylactic recommendations.
TERMINOLOGY DEFINITIONS
Venous thrombosis results from the process of thrombi 
formation within the veins. In most cases, venous throm-
bosis develops in lower limbs, more precisely in the drain-
age area between deep muscles and thus is called DVT. The 
cut-o point for the aected area location is the highest 
level the thrombus has reached, being proximal when it 
goes beyond the popliteal region and distal if it is con-
fined to the calf. Over DVT course, a thrombus ascend-
ing extension to the popliteal region and/or to the groin 
(proximal extension) can occur14,16-18. In the thrombus ex-
tension phase, the clot is friable and could break up, creat-
ing fragments (emboli). Thrombus migration to the lung 
could block the pulmonary artery or its branches, leading 
to PE14,16-18. The PE localization will be central, segmentar 
or subsegmentar, according to the most proximal aected 
extremity19. Both processes, DVT and PE, by being con-
tinuous from a pathological perspective, can be grouped 
as VTE18,20. The preventive measures for VTE are termed 
thromboprophylaxis or venous thromboprophylaxis13.
Patients suering from a VTE episode have a high 
recurrence risk and the possibility of late complications, 
such as post-thrombotic syndrome (PTS) and chronic 
thromboembolic pulmonary hypertension (CTEPH). The 
risk for thromboembolic recurrence is higher over the first 
months following the initial event, being 7% to 14% over 
the first three months and up to 30% within eight years21-23. 
PTS is characterized by chronic swelling of the aected 
leg, venous valvular function loss, cutaneous discoloration 
and ulceration. PTS aects 2% to 10% of patients suer-
ing from VTE, and may develop in up to 10 years after 
VTE until becoming clinically detectable17,24. On the other 
hand, up to 4% of patients with VTE can develop CTEPH 
over the first 2 years from the initial embolic event25. These 
complications reduce the quality of life and are associat-
ed with morbidity, resulting in economic burden for the 
health system26.
VENOUS THROMBOEMBOLISM DIAGNOSIS
Generally, patients with DVT present with a painful or 
sore venous area, erythema or swelling in the aected 
limb. Physical examination enables the identification of 
palpable venous chords representing a thrombosed vein or 
a superficial vein dilatation. Dierential diagnosis of DVT 
includes ruptured Baker’s cyst, muscular and tendinous 
tears, infeccious cellulites, among others17-18. The purely 
clinical diagnosis of DVT, based on signs and symptoms, 
is inaccurate and insensitive, with only one-third or less of 
clinical suspicion being confirmed through imaging stud-
ies18,27. A meta-analysis of a clinical evaluation to diagnose 
DVT showed that confirmation is more frequent in the 
presence of malignity [likelihood rate (LR) = 2.7], previous 
VTE (LR = 2.3), recent immobilization (LR = 2.0), recent 
surgery (LR = 1.8) and calf circumference dierence (LR = 
1.8). On the other hand, only the absence of swelling (LR 
= 0.7) and the dierence between calf circumference (LR = 
0.6) contributed to rule out DVT diagnosis28.
Patients with suspect DVT can be evaluated by the ap-
plication of clinical probability models. The probabilistic 
modeling helps to guide medical management according 
to the clinical probability calculated18,29.
Until very recently, contrast-enhanced phlebography 
was considered the gold standard of DVT diagnosis. How-
ever, apart from being an invasive test, phlebography still 
requires a trained practicioner to be done, and this practi-
tioner is seldom available in emergency rooms even in hos-
pitals. Still, phlebography cannot be repeated many times 
to monitor the developmento of DVT. In a significant ratio 
of symptomatic patients, podal vein puncture for contrast 
medium injection is not feasible because of swelling, pain, 
or di cult approach16.  Another possible problem of phle-
bography is that it can not visualize the distal venous sys-
tem, or detect clinically insignificant thrombi16.
Alternative studies for DVT tracking include radionu-
clide imaging with labeled fibrinogen and venous ultra-
sound. Both present low sensitivity to distal DVT16. Meta-
analysis of orthopedic patients applying isotope methods 
shows 45% sensitivity for lower limb DVT and 92% espe-
cificity16.
Duplex ultrasonography scan presents 39% sensitiv-
ity and 98% specificity in symptomatic hospitalized pa-
tients. In patients undergoing arthroplasty, the numbers 
decrease to 13% and 92%, respectively16. The ultrasound 
test performance in defining symptomatic DVT is better 
in proximal DVT30.
The computed tomography phlebography shows 
similar results to ultrasound tests in DVT concerning 
clinical significance. In hospitals, the diagnostic imaging 
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technique chosen for DVT usually follows criteria of pa-
tient safety, cost of diagnostic technique, and time to have 
the exam done16.
Over the last decade, laboratory tests to detect D-di-
mers (DD) in the diagnostic strategy of DVT were intro-
duced. This measure goal was to improve the accuracy of 
noninvasive clinical diagnostic strategy. DD test can be 
especially useful when there is a low clinical probability 
of DVT for a patient. In this setting, a negative result in-
dicates a low clinical probability of DVT, which is su -
cient to exclude the diagnosis, even in the absence of an 
imaging study. However, as it is poorly specific, positive 
results can occur in postoperative states, severe infections, 
and neoplasms, even in the absence of VTE18,27,31. Even the 
Wells’ model of structured clinical rules for DVT alone 
is inappropriate to define or exclude the DVT diagnosis. 
However, this model is accurate and safe enough to guide 
the subsequent diagnostic procedure27,32. Thus, excluding 
DVT diagnostic can be possible in certain clinical circum-
stances without resorting to an imaging study.
DD test can also be useful in patients with high clini-
cal probability of DVT and ultrasound negative results. 
In this case, a negative DD test would avoid a repeated as-
sessment by imaging studies the following weeks. These 
strategies are economically sparing and assure diagnostic 
safety for the patient27,32. Variations of DD laboratorial 
performance can allow patients in a intermediate risk 
category to have DVT diagnosis excluded without under-
going imaging studies29. However, only imaging studies 
usually can confirm the diagnosis, especially lower limb 
ultrasonography27,32.
Clinically, PE may present a clinical condition 
of sudden dyspnea, occasionally associated with 
hemoptysis, pleuritic chest pain, arterial hypotension or, 
in extreme cases, circulatory shock resulting from acute 
right heart failure. The most prevalent PE symptoms 
are dyspnea (present in 73% of patients), pleuritic pain 
(69%) and cough (37%). The most important signs are 
tachypnea (70%), rales (51%), and tachycardia (30%). 
Cardiorespiratory arrest and circulatory collapse can 
develop in severe cases. Electrocardiographic signs 
include sinus tachycardia and, less often, atrial fibrillation, 
right bundle-branch block or other right ventricular 
strain findings, such as a S1Q3L3 pattern. In a meta-
analysis of PE diagnostic clinical evaluation, syncope 
alone (LR = 2.4), shock (LR=4.1), thrombophlebitis 
(LR=2.2), concomitant DVT (LR=2.1), lower limb 
swelling (LR=2.1), sudden dyspnea (LR=1.8), active 
neoplasm (LR=1.7), recent surgery (LR=1.6), hemoptysis 
(LR=1.6), and lower limb pain (LR=1.6) showed to 
be valuable for confirming PE. On the other hand, the 
absence of sudden dyspnea (LR=0.4) and the absence of 
any dyspnea (LR=0.5) or tachypnea (LR=0.6) contribute 
to rule out DVT33.
Patients with suspect PE represent a medical urgency 
due to high mortality and morbidity related. Many patients 
do not present DVT symptoms in lower limbs, although 
conversely many symptomatic DVTs are associated 
with asymptomatic PE. Similarly to DVT, PE models of 
clinical probability were developed to help the diagnostic 
approach1-3,18,34,35.
Pulmonary angiography is the gold standard test to di-
agnose PE, although it is an invasive procedure associated 
with increased morbidity and mortality.36
Pulmonary scan is a more widespread diagnostic pro-
cedure and traditionally constitutes an objective study to 
diagnose PE. A normal pulmonary scan practically rules 
out PE. However, PE could be present in cases of low- or 
intermediate probability pulmonary scan. In this context, 
other exams can be required. Excluding low- or interme-
diate probability patients, a high probability pulmonary 
scan sensitivity is 77.4%, while a normal or low probabilil-
ity pulmonary scan specificity is 97.7%. The percentage of 
patients with confirmed or ruled out diagnosis using pul-
monary scan is 73.5%37.
Recently, the pulmonary spiral computed tomogra-
phy (multislice pulmonary helical computed tomography 
or computed angiotomography), by employing contrast 
media, gained acceptance in diagnosing PE, as it has the 
advantage of evaluating other pulmonary structures and 
other thoracic organs at the same time it evaluates the pos-
sibility of PE18,27,31.
The pulmonary scan was not considered an inferior 
diagnostic method compared to angiotomography38. Me-
ta-analysis by Hayashino et al.39 suggested the angiotomo-
graphy presents higher discriminatory power to rule out 
PE compared to pulmonary scan in patients with low PE 
probability. On the other hand, in patients with high PE 
probability, the methods seem equivalent39.
A meta-analysis studying PE diagnosis calculated posi-
tive LRs in 18.3 for high probability pulmonary scan and 
24.1 for pulmonary angiotomography ,16.0 for lower limb 
ultrasonography. The negative LR for normal pulmonary 
scan was 0.05. For negative pulmonary angiotomography 
and negative ultrasonography, the negative LR is 0.04 for 
both. A DD result below 500 mg/L presents negative LR 
0.08.35 The diagnostic approach to PE can be directed to 
the dierent categories of clinical risks, with later defini-
tion of diagnostic procedure1-3,34,35.
VENOUS THROMBOEMBOLISM EPIDEMIOLOGY
VTE is a public health matter. In the United States there 
are at least 200,000 new cases diagnosed annually40. The 
annual incidence in the United States is calculated as one 
case per 1,000 in the population, with one-third corre-
sponding to PE.4 In Europe, the annual estimates of symp-
tomatic VTE incidence are 1.48 cases per 1,000 population 
for DTV and 0.95 per 1,000 population for PE20.
MARCOS DE BASTOS ET AL.
90 Rev Assoc Med Bras 2011; 57(1):87-97
VTE occurs in community patients (primary care lev-
el), but it is much more prevalent in hospitalized patients 
(tertiary care level). Sixty to 70% of all VTE population 
burden is estimated as being associated with hospitaliza-
tion15,34,41,42. Although most medical studies of VTE in 
hospitalized patients focus the patient status during hos-
pitalization, the fact that the patient has been hospitalized 
is, per se, a risk factor for VTE after discharge, with most 
symptomatic VTEs associated with hospitalizations oc-
curring after discharge13,42,43. Some studies show VTE after 
discharge is up to three times as frequent as during hos-
pitalization43. Although many authors define thromboem-
bolic risk is higher within 4 weeks from hospitalization, 
this risk can persist for up to 3 months42,43. Thus, the sepa-
ration between hospital-acquired VTE and community-
acquired VTE is to some extent artificial43.
Although VTE risk during hospitalization is historically 
associated with surgical complications, more than a half 
(50% to 75%) fatal hospital thromboembolic events occur 
in medical patients, since their number is superior to that of 
surgical patients44-46. In 2003, for instance, from 38 million 
hospital discharges from departments of medical urgencies 
in the United States, 24 million were medical hospitaliza-
tions while 8 million were surgical hospitalizations.
Surgical procedures increase VTE risk, with an OR 
of 21.722. Even in gynecological surgeries, OR can reach 
a value of 1122. The length of surgery is to be considered, 
with an operative time longer than 30 minutes seeming to 
be the cut-o value for thromboembolic risk definition17. 
The surgical procedures performed under general anes-
thesia have a two-fold higher thrombotic risk, compared 
to epidural and spinal anesthesia17.
Between 40% and 80% of patients hospitalized for ma-
jor orthopedic surgery receiving no prophylaxis present 
with documented thromboembolic events. Up to 10% of 
these patients have fatal PE17. But the VTE incidence in 
hospitalized patients in medical or general surgery unities 
varies from 10% to 40% in the absence of thrombopro-
phylaxis8. Similar proportions are found in patients after 
a stroke. Up to a quarter of patients with an acute myocar-
dial infarction may suer VTE with no thromboprophy-
laxis18. When patients are grouped by clinics and they are 
given no thromboprophylaxis, VTE risk can be consider-
able, as it is demonstrated in Table 1.
Among hospital discharges in 944 intensive care uni-
ties in the United States, postoperative VTE has been the 
second leading cause for complications and the third lead-
ing cause for mortality and excess cost8. After adjusting for 
comorbidities, survival after PE is three months shorter 
than after DVT47.
In the United Kingdom, VTE is associated with the 
death of 25,000 to 32,000 inpatients annually and is the 
immediate cause of death in 10% of all patients who die in 
hospital14. In one-fifth or VTE patients, the clinical events 
will develop so rapidly that no medical intervention can 
be allowed40. In about 70% to 80% of patients dying in a 
hospital as a result of PE, this initial diagnosis was not con-
sidered prior to death13.
In a postmortem study with 1,234 patients dying up to 
30 days after a surgery, PE proportion was 32%, with PE 
being considered death cause in 29% of PE patients13. Risk 
factors for early mortality in hospitalized patients include 
recurrent episode of PE, old age, neoplasm, and underly-
ing cardiovascular disease18. Despite the advances in care 
and the reduced length of stay in the hospital contribute to 
mitigate some of the VTE risk factors, inpatients currently 
may present higher VTE risk than in the past because of 
the current population older age. The population aging fa-
vors increased neoplasm prevalence, more intensive anti-
neoplastic therapies, more extended and complex surgical 
procedures, and ultimately longer stays in hospital13.
It is simplest to define clinically the patients at risk for 
VTE than identifying asymptomatic DVT and PE in hos-
pitalized patients with other diseases. VTE is a clinically 
di cult secondary diagnosis, remaining occult or being di-
agnosed as another disease, such as cellulitis, venous insuf-
ficiency, tendinitis, pneumonia, myocardial infarction, and 
viral pleurisy among others43. Although venous thrombo-
prophylaxis studies use accurate diagnostic strategies, most 
events are caused by distal DVT often silent. In 10% to 20% 
of patients with distal DVT, a thrombus proximal extension 
occurs. There is an association between asymptomatic DVT 
and later development of symptomatic PE. Thus, even as-
ymptomatic DVT cases require clinical care13.
VTE is a clinical condition of high cost to health sys-
tems. Most patients require one or more imaging diagnos-
tic studies, treatment with injectable anticoagulant drugs, 
such as unfractionated heparin (UFH) or low molecular 
weight heparins (LMWH), and a potentially long stay in 
the hospital48. After hospital discharge, the patient will still 
use oral anticoagulant for a varying period, depending on 
the event clinical circumstance49. There is still the possibil-
ity of recurrence and sequels, such as PTS and CTEPH49.
Table 1 – Venous thromboembolism risk for patients 






Medical clinic 10 to 20
General Surgery 15 to 40
Major gynecologic surgery 15 to 40
Neurosurgery 15 to 40
Stroke 20 to 50
Hip or knee replacement 40 to 60
Major trauma 40 to 80
Spinal cord injury 60 to 80
Intensive Care 10 to 80
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In 1993, the annual burden in the United Kingdom 
from postsurgical VTE therapy was 223 million pounds14. 
The total annual cost both direct and indirect from VTE 
treatment is estimated at 640 million pounds14. In the 
United States, the annual expenditures with each VTE 
event vary from US$7,594 to US$16,64426.
VENOUS THROMBOEMBOLISM RISK FACTORS
Dierent VTE risk factors can lead to a hypercoagulable or 
prothrombotic state, to a vascular pooling or to venous en-
dothelium damage, as described in Virchow’s triad18. VTE 
episodes can be elicited by risk (physiological or patho-
logical) situations or associated diseases (secondary VTE) 
or be unrelated to any condition (idiopathic VTE). VTE 
risk factors are identified in 50% to 75% of inpatients, with 
about 40% of them presenting three or more risk factors8.
Age-associated VTE risk is similar to an exponential 
function, varying from one event per 10,000 people/year 
in patients under 40 years to one event per 1,000 people/
year at the seventh decade. Above 80 years of age, the risk 
can increase to one in 100 patients-year17. The mean VTE 
diagnosis age is 62 years old, with 44% presenting PE and 
14% DVT-associated PE50. The PE proportion among 
those having VTE increases with age in males and females. 
TVE risk is growing important as a public health issue due 
to population aging.
There seems to be a VTE incidence variation accord-
ing to ethnicity. Some studies suggest a higher VTE in-
cidence in Caucasians and in Afro-descendants, with an 
intermediate incidence among Hispanics and a low inci-
dence in Asians40.
Another risk factor is malignancy. Up to 20% of com-
munity-acquired VTE are associated to neoplasms8. Can-
cer and VTE association can be caused by antineoplastic 
surgeries, immobilization, chemotherapy use, hormone 
therapy use, central catheter implants, and bedridden con-
dition8. Often, a neoplasm is still occult at the moment 
VTE occurs, being detected only during clinical follow-up 
(paraneoplastic syndrome). The main malignancies asso-
ciated with VTE are hematological, renal, ovarian, pancre-
atic, gastrointestinal and pulmonary in nature18. OR values 
between 2 and 9 are representative of the association be-
tween VTE and malignancy22,51.
VTE risk is higher in patients with hereditary throm-
bophilias, including several hemostatic defects, such as 
activated protein C resistance, natural anticoagulant de-
ficiencies, such as protein S, C, and antithrombin, and 
prothrombotic mutations known as factor V Leiden and 
prothrombin gene G20210A mutation17,18,52,53. Acquired 
thrombophilias, such as the antiphospholipid syndrome, 
characterized by the presence of antiphospholipid anti-
bodies – lupus anticoagulant and anticardiolipin anti-
bodies – are also associated with higher VTE risk17,18,52,53. 
Other determinants less evaluated clinically, include in-
creased factor VIII, fribinogen, factor IX, factor XI, and 
homocysteine levels among others18,53. The magnitude of 
the association between VTE and thrombophilia, in OR, 
varies between 2 and 951.
Obesity, defined as body mass index above 30 kg/m2, 
increases VTE risk by up to three times. This increase may 
be due to immobilization or coagulation activation17,51.
Varicose veins increase VTE risk by 1.5 times when 
associated with major surgeries or large orthopedic sur-
geries (hip and knee replacement, hip fracture surgery). 
However, risk seems to be reduced in patients undergo-
ing varicose vein repair surgery17. Another study suggested 
the presence of varicose veins is a relatively low-risk factor, 
with OR below 251.
Immobilization due to lower limb paralysis, casts 
or bed confinement for longer than three days increases 
thrombotic risk up to ten times, with a cumulative eect 
in time17. In other studies, a long bedridden condition was 
considered a relatively low-risk factor, with OR < 2. Lower 
limb paralysis associated with a neurological condition, on 
the other hand, has an OR of approximately 322,51. There is 
an increased VTE risk with an OR < 2 in individuals who 
remain seated for a long time, such as in long air travel51.
Severe trauma and spinal cord injury increase VTE 
risk by over 10 times22,51.
Other risk factors include congestive heart failure, ear-
ly period (three weeks) after acute myocardial infarction 
and stroke, in addition to severe infections, polycythe-
mia, multiple myeloma, chronic inammatory bowel dis-
eases (ulcerative retocolitis or ileitis), nephrotic syndrome 
among others17,51.
Pregnancy, specially the postpartum period, increases 
thrombotic risk by 2 to 20 times22,51,54. Combined oral con-
traceptives, hormone replacement therapy, raloxifene, and 
tamoxifen increase thromboembolic risk by three times. 
There is no evidence that low-dose progestogens used 
alone as contraceptives favor VTE17.
Acute medical disease, such as respiratory insu cien-
cy and congestive heart failure, increase thrombotic risk 
by up to 10 times17,51. A previous VTE is also an important 
thromboembolic risk factor, with OR between 2 and 951. 
There also seems to be an associations between thrombo-
phlebitis and VTE, with a population study indicating OR 
4.522. Indwelling central vein catheter and pacemaker in-
sertion are associated with venous thromboembolic risk, 
with OR 5.622.
THROMBOEMBOLIC RISK STRATIFICATION IN HOSPITALIZED 
PATIENTS
Fatal PE prevention should not be the only thrombopro-
phylaxis purpose, with proximal or distal DVT and PE 
prevention being important additional purposes, whether 
they are symptomatic or not, because of their morbidity, 
cost, and hospital length of stay8.
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The thromboprophylaxis recommendation in hospital-
ized patients is based on studies monitoring asymptomatic 
and symptomatic DVT occurrence. Profound DVT, iden-
tified by imaging study in screening risk groups, has an 
incidence 10 to 30-fold higher than that found in symp-
tomatic DVT studies55. Such a result tends to overrate 
thromboprophylaxis cost-eectiveness and benefits. Based 
on symptomatic patient studies, the number necessary to 
avoid a VTE is high, i.e., ranging from 150 to 1,600, and the 
cost-eectiveness ratio is unreliable55. On the other hand, 
although the number of VTE cases grows quite a lot by in-
cluding asymptomatic cases, the clinical significance of as-
ymptomatic VTE prevention is unknown16. The inclusion 
of asymptomatic DVT as an endpoint in thromboprophy-
laxis studies has been rejected specially in orthopedic sur-
geries due to the discrepancy between DVT phlebographic 
prevalence and the low risk for symptomatic VTE, even 
in high thromboembolic risk patients17. The Scottish In-
tercollegiate Guideline Network (SIGN) claims that reduc-
ing asymptomatic DVT also reduces symptomatic DVT, 
asymptomatic and symptomatic PE, including fatal PE17.
VTE risk factors can be basically grouped in two ways. 
The most usual way is grouping risk factors into risk cat-
egories, i.e., inpatients, defined conditions, medical wards 
or surgical wards8,13. This process, in surgical patients, in-
volves risk factors allocation into three or four risk catego-
ries based on surgery type (e.g., minor or major surgery), 
patient’s age (adult or elderly), presence of additional risk 
factors (e.g., neoplasm, trauma, comorbidity or previous 
VTE, among others). There is great variability among dif-
ferent proposals and even among thromboprophylactic 
regimens14,50. Even after identification of TVE group risks, 
it is not possible to predict the individual patient in any 
risk group who will develop the thromboembolic event13.
The recommendations from the 8th American College 
of Chest Physicians (ACCP) Consensus Conference sup-
port this approach8,13. In short, the classification of low 
thromboembolic risk patients includes those undergoing 
minor surgeries or patients with medical conditions, but 
entirely ambulatory. Intermediate (moderate)-risk patients 
comprise those undergoing open general, gynecologic or 
urologic surgeries, and medical patients with restricted 
mobility with no free ambulation. High-risk patients in-
clude those undergoing a major orthopedic surgery, multi-
ple trauma cases, and those with spinal cord injury8,13. This 
approach has been suggested and updated for many years, 
but the attending physicians have not adhered to it10-12,56,57.
The other approach used for thromboprophylaxis in 
hospitalized patients is the generation of formal models to 
assess VTE risk. This approach is standardized and assess-
es a list of risk factors in all patients. Thromboembolic risk 
factors are then grouped into risk categories and throm-
boprophylaxis is suggested for each risk category. This ap-
proach is more di cult to implant than the previous one, 
as it requires information technology or systematic organi-
zation of patients’ information ow. Many argue that this 
approach has not been formally tested and that there is no 
formal understanding about interaction among several 
risk factors to define the patient status inside the throm-
boembolic risk spectrum. Another argument against this 
approach is that the individual prophylactic strategy has 
not undergone strict clinical assessment, with risk indi-
vidualization being logistically complex8,13.
The development of either local or nationwide clinical 
recommendations for thromboprophylaxis has still been 
controversial. However, the use of specific updated recom-
mendations for thromboprophylaxis is suggested for every 
hospital care setting10,17,56,57. Table 2 summarizes the main 
pharmacological thromboprophylaxis regimens.
INTERNATIONAL STUDIES ON THROMBOPROPHYLAXIS
ENDORSE
This study, the International Day for the Evaluation of Pa-
tients at Risk for Venous Thromboembolism in the Acute 
Hospital Care Setting (ENDORSE), collects information on 
thromboprophylactic practices and compares VTE risk in 
dierent inpatient populations over 40 years of age and ad-
mitted to medical wards or over 18 years of age andadmitted 
to surgical wards. It is a multicentric cross-sectional study 
with 358 hospitals participating, designed to measure the 
prevalence of VTE and risk factors, and the recommended 
thromboprophylaxis is based on the 7th 2004 ACCP Con-
sensus Statement. The results reported in 2008 included 
68,183 patients, with 30,827 (45%) of them being surgical 
patients. The mean percentage of patients at risk for VTE 
is 51.8%, ranging among countries from 35.6% to 72.6%. 
Among patients at risk, 19,842 (64.4%) are from surgical 
wards. Among surgical patients at risk, 11,613 (58.5%) were 
receiving the recommended thromboprophylaxis. The vari-
ation between countries was 0.2% to 92.1%. Among medical 
patients at risk for VTE, 6,119 (39.5%) patients were given 
the advocated thromboprophylaxis. The variation between 
countries was 1% to 70.4%11.
Heparin type Regimen
Unfractionated heparin 3,500 to 5,000 units SC q8 or 12h 
or 7,500 units SC q12h
Low molecular weight heparin
Enoxaparin 30 mg SC q12h starting 12 to 24h 
before the surgery or 40 mg/day 
SC starting 10 to 12h before the 
surgery
Dalteparin 5,000 units SC starting 12h before 
the surgery
Nadroparin 40 U anti Xa/kg SC for 3 days 
starting 2h before the surgery and 
then 60 units anti Xa/kg SC for day 
SC: subcutaneous route.
Table 2 – Recommendation of heparin thromboprophylactic 
regimen for medical and surgical inpatients40
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In January 2010, Kakkar et al.12 updated data on surgi-
cal ward inpatients and applied multivariate analysis for 
thromboprophylaxis used. It included 18,461 patients, 
17,084 (92.5%) of which were considered at risk for VTE. 
The thromboprophylaxis was used in 10,638 (62.3%) pa-
tients at risk. The use of thromboprophylaxis varied with 
the type of major surgery from 86% for orthopedic surgery 
to 53.8% in urology/gynecology and to 53.6% in other sur-
geries. Major orthopedic surgery was the procedure most 
strongly associated with thromboprophylaxis. Hip re-
placement was associated with OR = 6.2, followed by knee 
replacement, with OR = 5.912.
IMPROVE
Another International Initiative, the International Medi-
cal Prevention Registry on Venous Thromboembolism 
(IMPROVE) assessed thromboprophylactic practices in 
medical inpatients at risk for VTE. It is an observational 
study, in which hospitals registered the first 10 medical 
patients acutely ill every month. The treatment was de-
fined by the attending physician. The analysis of 15,156 
patients from 52 hospitals in 12 countries between July 
2002 and September 2006 shows that 50% of patients 
were receiving pharmacological or mechanical throm-
boprophylaxis. In the United States, 52% of patients (in 
other countries, 43% of patients) should havereceived 
thromboprophylaxis according to the ACCP recom-
mendations. Only 60% of patients at risk in both country 
categories received thromboprophylaxis. Unfractionated 
heparins were the most often used pharmacological ap-
proaches in the United States (21%), while low-molecu-
lar weight heparins were more often used in other coun-
tries (40%). There was also a variation regarding graded 
compression stockings and intermittent pneumatic com-
pression (IPC) between the United States and the other 
countries10.
PROPOSALS REGARDING THROMBOPROPHYLAXIS PROGRAMS
PROPOSAL OF THE 8TH AMERICAN COLLEGE OF CHEST PHYSI-
CIANS CONSENSUS MEETING
The latest ACCP publication presents the evidence-based 
recommendations8. The most important according to the 
recommendation level and study quality are shown in 
Table 3.
Some class societies, such as those in the fields of Or-
thopedics, Anesthesiology, Oncology, Gynecology and 
Obstetrics, adopt standard recommendations for throm-
boprophylaxis58-62.
Table 3 – Main prophylactic recommendations according to the 8th American College of Chest Physicians Consensus 
Meeting8,80
Recommendation (recommendation level and evidence degree)*
1) Every hospital should develop a formal strategy for venous thromboprophylaxis (1A)
2) Do not use salicylates alone for thromboprophylaxis (1A)
3) Use mechanical methods in high bleeding risk patients (1A)
4) Use mechanical methods to assist pharmacological thromboprophylaxis in mid- or high thromboembolic risk patients and 
high bleeding risk (2A)
5) Use LMWH, UFH minidose or pentasaccharide in patients undergoing large surgeries (1A)
6) Use routine thromboprophylaxis for all patients undergoing large gynecological or urological surgeries with LMWH, UFH 
minidose, pentasaccharide, or mechanical methods (1A)
7) Apply as a routine LMWH pentasaccharide or oral anticoagulants with a target-INR 2.5 (range from 2-3) to patients undergoing 
elective hip or knee replacement (1A)
8) Apply as a routine pentasaccharide (1A), LMWH (1B), oral anticoagulants with a target-INR 2.5 (recommendation 1B) or 
UFH (1B) to patients with hip fractures.
9) Maintain thromboprophylaxis for at least 10 days in patients undergoing major orthopedic surgeries (1A). In hip replacement 
and hip fracture, prophylaxis should be extended for over 10 days up to 35 days (1A).
10) Apply thromboprophylaxis to every patient with major trauma and spinal cord injury (1A)
11) Use thromboprophylaxis with LMWH, UFH or pentasaccharide in patients admitted to hospital with acute medical 
disease (1A)
12) Evaluate venous thromboembolic risk in all patients admitted to an Intensive Care Unit and apply thromboprophylaxis to 
most patients (1A)
*Notes: Level 1 recommendation refers to a robust recommendation in which the benefits overcome risks and cost. Level 2 indicates patient 
individual values might cause different choices, representing weaker recommendations than at level 1. It further indicates the risks, benefits, 
and cost magnitude is less well defined than at Level 1 recommendation. Evidence level may originate from high-, mid- or low-quality studies, 
indicated by letters A, B or C, respectively. UFH: unfractionated heparin; LMWH: low molecular weight heparin.
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CAPRINI’S PROPOSAL
This is a standard risk assessment model (RAM) origi-
nally proposed in the 80s and recently revised63,64. Caprini 
recommends the universal thromboembolic risk assessment 
applying the Evanston Northwestern Healthcare’s Throm-
bosis Risk Factor Assessment scores in a standard form. 
This tool lists several VTE risk factors and can be completed 
by a health team member based on a patient’s interview64. 
The tool recommends assigning weights from 1 to 5 to each 
risk factor. A cumulative score of all identified risk factors 
with their respective weights is used to stratify for each pa-
tient’s thromboembolic risk and indicate the recommended 
thromboprophylaxis64. The model rationale is to associate 
thromboprophylactic regimens with thromboembolic risk 
categories. In the original study, 538 surgical patients were 
prospectively assessed according to the presence of 20 risk 
factors. The presence of each risk factor was given one point. 
The total score defines the thromboembolic risk category as 
low-(below two), mid-(between two and four) or high-risk 
(5). General care steps are recommended for all risk catego-
ries, and pharmacological thromboprophylaxis is recom-
mended for mid- and high-risk patients in varying dosages.
The revised tool classifies thromboembolic risk factors 
with a score of 1 to 5. Risk factors classified as equivalent to 
1 point are considered relatively minor factors, while those 
with a higher score are considered more important factors 
regarding thromboembolic risk. The cumulative score for 
a all risk factors determines the patient’s thromboembolic 
risk range. The protocol recommends that patients with a 
cumulative score above two should be given either phar-
macological or mechanical thromboprophylaxis. Patients 
with cumulative score 5 should be given pharmacological 
prophylaxis alone or associated with mechanical methods64.
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE PROPOSAL
According to the National Institute for Clinical Excellence 
recommendations65, the priorities for implantation of throm-
boprophylactic recommendations in surgical patients are:
– patient assessment to identify the thromboembolic risk;
– health professionals should provide the patient with 
oral and written information about VTE risk and thrombo-
prophylaxis eectiveness before the surgery;
– selected patients should be oered graded compres-
sion stockings since admission. Stockings must follow tech-
nical compression standards. Patients should be instructed 
on the way of dealing with the stockings, and health team 
should encourage and monitor their use;
– use of IPC or foot devices as an alternative or in as-
sociation with graded compression stockings;
– high thromboembolic risk patients and orthopedic 
surgical patients should be oered pharmacological throm-
boprophylaxis with LMWH associated with mechanical 
thromboprophylaxis. Pentasaccharide can be used as an al-
ternative to LMWH;
- maintenanceof thromboprophylaxismedicationfor 
4weeks after hip surgery
– favor regional anesthesia over general anesthesia;
– promote the patient ambulation as soon as possible 
after surgery65.
BRAZILIAN THROMBOPROPHYLAXIS STUDIES
In Brazil, PE and DVT diagnosis and Treatment guidelines 
approaching thromboembolic risk factors, risk stratifica-
tion, and thromboprophylactic recommendation are sup-
ported by the Brazilian Medical Association (Associação 
Médica Brasileira – AMA)66-68.
Deheinzelein et al. described the thromboembolic risk 
and application of thromboprophylactic strategies in four 
facilities in São Paulo with 1,454 patients (589 surgical 
patients and 865 medical patients). This study using Cap-
rini’s risk stratification showed 29% of high VTE risk pa-
tients were not given thromboprophylaxis. Still 27% of low 
thromboembolic risk patients were given the prescribed 
thromboprophylaxis69.
Another study, developed from October 1995 to Au-
gust 1999 in a public Brazilian Navy hospital in Rio de Ja-
neiro, enrolled 18,690 patients70,71. By adopting Caprini’s 
risk stratification, 4.7% of patients were classified as high-
risk patients, 8,012 (42.9%) as intermediate-risk patients, 
and 52.4% as low-risk patients. The recommended pro-
phylaxis was adopted in 47.1% of high-risk patients. On 
the other hand, 4.6% of low-risk patients were given phar-
macological prophylaxis even with no indication70,71.
Over a thromboprophylaxis assessment in a univer-
sity hospital, Franco et al.72 developed a cross-sectional 
study in seven wards at Conjunto Hospitalar de Sorocaba 
from August 2004 to August 2005. When stratifying for 
DVT risk, clinical and surgical factors derived from Cap-
rini’s model were investigated. Two hundred and sixteen 
medical records, 121 from surgical wards, 31 from medi-
cal wards, 31 from an intensive care unit, and 33 from 
gynecology/obstetrics wards were analyzed. Thrombo-
prophylaxis was prescribed in 57 (26%), with 51 (89%) 
receiving a correct prescription. The most used prophy-
lactic method was pharmacological; 49 from 57 patients 
used LMWH. Compression stockings were used in five 
patients, early ambulation in seven and IPC was not used.
Pereira et al.73 performed, from March to May 2007, 
a prospective study with inpatients at Roraima General 
Hospital. The purpose was to find thromboprophylaxis 
applied to inpatients. The thromboembolic risk strati-
fication followed Caprini’s model. From 850 patients, 
557 (66.7%) were medical patients. Overall, 353 patients 
(41.6% of the total) were low-risk patients, 411 (48.3%) 
were intermediate-risk patients, and 86 (10.1%) were 
high-risk patients for VTE. Only 24% of patients who 
should receive pharmacological thromboprophylaxis ac-
tually received it73.
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Another cross-sectional observational study on 
thromboprophylactic practice included 1,036 patients in 
three Manaus hospitals from January to March 2006. The 
risk stratification used was Caprini’s proposal. The VTE 
risk was high in 50.6% of hospitalizations, intermediate 
in 18.6% of the hospitalizations and low in 30.8% of the 
patients. In 74% of moderate- or high-risk patients, phar-
macological thromboprophylaxis was not used74.
More recently, Rocha et al.68 created venous throm-
boprophylaxis formal structures to apply the venous 
thromboprophylaxis Brazilian guidelines supported by 
AMB to medical patients from four hospitals in Bahia. 
The intervention included  the disclosure of guideline 
through lectures and algorithms. The study design was 
cross-sectional with a thromboprophylaxis assessment 
both before and after the intervention. The authors con-
cluded that thromboprophylaxis is underused in Brazil-
ian hospitals and that the disclosure strategy and the con-
tinued education program are insu cient to improve the 
correct thromboprophylaxis indication75.
Another retrospective study also assessed the national 
guideline implantation for surgical patients in a university 
hospital76. The project disclosure involved an algorithm 
adoption, consensus meetings, disclosure in a healthcare 
team meeting and an introduction letter from the hospital 
administrative sta. The adherence to thromboprophylax-
is was inappropriate, although compression stockings have 
been more often prescribed76.
STRATEGY FOR IN-HOSPITAL THROMBOPROPHYLAXIS IM-
PLANTATION
There are strong scientific arguments for thrombopro-
phylaxis program implantation in hospitals7,8,43,56,57. The 
United State Agency for Health Care Research and Qual-
ity recently developed an administrative method of eval-
uation for a hospital thromboprophylaxis program im-
plantation77. Based on the intervention eectiveness and 
cost-eectiveness, the thromboprophylaxis in selected 
patients was the most outstanding step as an in-hospital 
practice to protect patients7.
National recommendations as the National Institute 
for Clinical Excellence’s (NICE) for healthcare services in 
England and Scotland17,65 were issued after more than a 
half of deceased patients from PE were found not to have 
received thromboprophylaxis although they showed risk 
factors and had no contraindication to standard throm-
boprophylaxis14,17.
Passive protocol delivery and thromboprophylactic 
strategy disclosure were unlikely to succeed8,17. Throm-
boembolic risk simple models integrated with in-hospital 
prescriptions are a key strategy to increase inpatient pro-
tection. This approach should generate electronic alerts 
regarding non-venous thromboprophylaxis prescription 
in patients at risk. This strategy should be complemented 
by the formation of specific multidisciplinary teams for 
venous thromboprophylaxis, by the thromboprophylaxis 
process monitoring and by thromboprophylaxis pre-
scription control through an internal audit78,79. National 
collaborations can accelerate the use of venous thrombo-
prophylaxis. Adoption of stimuli to prescribe thrombo-
prophylaxis was also suggested. Possibly regulatory steps 
in addition to local actions are required as in the United 
Kingdom14. Therefore, hospitals should have proven ac-
tive thromboprophylaxis program according to predeter-
mined standards.
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